Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Hans, van Eenennaam"'
Autor:
Xiaoyu Fan, Marta A. Ważyńska, Arjan Kol, Noemi Perujo Holland, Bruna Fernandes, Sander M. J. van Duijnhoven, Annechien Plat, Hans van Eenennaam, Philip H. Elsinga, Hans W. Nijman, Marco de Bruyn
Publikováno v:
EJNMMI Research, Vol 13, Iss 1, Pp 1-11 (2023)
Abstract Background CD103 is an integrin specifically expressed on the surface of cancer-reactive T cells. The number of CD103+ T cells significantly increases during successful immunotherapy and might therefore be an attractive biomarker for noninva
Externí odkaz:
https://doaj.org/article/42504525a87d43f6acda5c05efb66f5a
Autor:
Xibei Dang, Lars Guelen, David Lutje Hulsik, Grigori Ermakov, Edward J. Hsieh, Joost Kreijtz, Judith Stammen-Vogelzangs, Imke Lodewijks, Astrid Bertens, Arne Bramer, Marco Guadagnoli, Alexis Nazabal, Andrea van Elsas, Thierry Fischmann, Veronica Juan, Amy Beebe, Maribel Beaumont, Hans van Eenennaam
Publikováno v:
mAbs, Vol 15, Iss 1 (2023)
ABSTRACTMonoclonal antibodies have become an important class of therapeutics in the last 30 years. Because the mechanism of action of therapeutic antibodies is intimately linked to their binding epitopes, identification of the epitope of an antibody
Externí odkaz:
https://doaj.org/article/23e30f5d2f8c4516bac906e80f9ad9d7
Autor:
Caroline Robert, Ivan Marquez-Rodas, Michele Maio, Vanna Chiarion-Sileni, Piotr Rutkowski, Hans Van Eenennaam, Julien Villaudy, Jessica Kundapur, Ana Maria Arance, Alexander Eggermont, Guillemo De Velasco Oria de Rueda, Laura Lassouw-Polman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/f9ea6719961d432b9f55dceb25823da4
Autor:
Xin Lei, Indu Khatri, Tom de Wit, Iris de Rink, Marja Nieuwland, Ron Kerkhoven, Hans van Eenennaam, Chong Sun, Abhishek D. Garg, Jannie Borst, Yanling Xiao
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-14 (2023)
The presence of classical type 1 dendritic cells (cDC1) positively influences prognosis in cancer, but their intricate networking with the various T cell types found in the tumour microenvironment is not fully appreciated. Here the authors show that
Externí odkaz:
https://doaj.org/article/c8c7c60050dc41968a22f225d73ae370
Autor:
Danique Giesen, Hans van Eenennaam, Hans W. Nijman, Marco de Bruyn, Arjan Kol, Xiaoyu Fan, Marta A. Wazynska, Sander M.J. van Duijnhoven, Annechien Plat, Philip H. Elsinga
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 12 (2022)
Purpose CD103, an integrin specifically expressed on the surface of cancer-reactive T cells, is significantly increased during successful immunotherapy across human malignancies. In this study, we describe the generation and zirconium-89 (89Zr) radio
Externí odkaz:
https://doaj.org/article/f55b3137b2b94aa192c9ac5565a27b1d
Autor:
David Rosen, Laurence Fayadat-Dilman, Yiwei Zhang, Konstantin Dobrenkov, Elliot Chartash, Richard Wnek, Smita Mauze, Hans van Eenennaam, Judith Stammen-Vogelzangs, Ying Yu, Marco Guadagnoli, Lars Guelen, Thierry O Fischmann, Jerelyn Wong, Nikolina Bąbała, Jozef Wagenaars, Veronica Juan, Winnie Prosise, Maurice Habraken, Imke Lodewijks, Danling Gu, Jeanne Baker, David Lutje Hulsik, Lilian Driessen-Engels, Dan Malashock, Joost Kreijtz, Astrid Bertens, Evert de Vries, Astrid Bovens, Arne Bramer, Sean Troth, Svetlana Sadekova, Andrea van Elsas, Jason K Cheung, Jannie Borst, Amy M Beebe
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 9 (2022)
Background Immune checkpoint inhibitors (ICI) have radically changed cancer therapy, but most patients with cancer are unresponsive or relapse after treatment. MK-5890 is a CD27 agonist antibody intended to complement ICI therapy. CD27 is a member of
Externí odkaz:
https://doaj.org/article/cc59fd0a12e04837b4168ce751ae8a2b
Autor:
Erik Voets, Marc Paradé, David Lutje Hulsik, Sanne Spijkers, Wout Janssen, Joost Rens, Inge Reinieren-Beeren, Gilbert van den Tillaart, Sander van Duijnhoven, Lilian Driessen, Maurice Habraken, Peter van Zandvoort, Joost Kreijtz, Paul Vink, Andrea van Elsas, Hans van Eenennaam
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-15 (2019)
Abstract Background Accumulating preclinical data indicate that targeting the SIRPα/CD47 axis alone or in combination with existing targeted therapies or immune checkpoint inhibitors enhances tumor rejection. Although several CD47-targeting agents a
Externí odkaz:
https://doaj.org/article/7bdacc0cad7a402abca3856640245c5f
Autor:
Els Verdegaal, Hergen Spits, Remko Schotte, Martijn Kedde, Gemma Moiset, Hans Van Eenennaam, Pauline van Helden, Sjoerd van der Burg, Julien Villaudy, Wouter Pos, Daniel Go, Christien Fatmawati, Etsuko Yasuda, Madalina Cercel, Esmay Frankin, Susan van Hal
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/db80a70a00dd4578b39f1f849964e0ec
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Persistent antigen exposure in chronic infection and cancer has been proposed to lead to cytotoxic T lymphocyte (CTL) “exhaustion”, i.e., loss of effector function and disease control. Recent work identifies a population of poorly differentiated
Externí odkaz:
https://doaj.org/article/01e4c58a73e045768e15e740f92a1582
Autor:
Deepak Mittal, Dipti Vijayan, Joost Neijssen, Joost Kreijtz, Maurice M. J. M. Habraken, Hans Van Eenennaam, Andrea Van Elsas, Mark J. Smyth
Publikováno v:
OncoImmunology, Vol 8, Iss 11 (2019)
A significant proportion of human epidermal growth factor receptor 2 (Her2/ErbB2)-positive metastatic breast cancer patients are refractory to Her2-targeted trastuzumab-like therapy. Some of this resistance has been attributed to the upregulation of
Externí odkaz:
https://doaj.org/article/bf7b49e859c24b6f93fc34fdf41d56fe